Insurance approval rates for clinical trial participation rose under Affordable Care Act
Bottom Line: Approval rates for privately insured patients seeking to enroll in oncology clinical trials increased after the passage of the Affordable Care Act.
Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research.
Authors: David S. Hong, MD, deputy chair and associate professor in the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston; and Kenneth L. Kehl, MD, a member of MD Anderson's Division of Cancer Medicine.
Background: explained that since 2000, publicly funded Medicare has covered the routine costs of clinical trial participation. Patients who were covered by private insurance often faced a patchwork of coverage options, with different insurers and different states determining whether participation in a clinical trial would be covered.
In 2010, the passage of the Patient Protection and Affordable Care Act (ACA) mandated that private insurers cover "standard of care" costs of clinical trial participation, effective Jan. 1, 2014. Hong, who oversees phase I clinical trials at MD Anderson, said that after the ACA mandate took effect, he perceived that patients in his practice were experiencing fewer delays in being approved for clinical trials, and undertook the study to see whether his observation was true on a larger scale.
How the Study Was Conducted and Results: Hong and colleagues analyzed 2,404 referrals from the departmental database of the Clinical Center for Targeted Therapy at MD Anderson, comparing rates of insurance clearance and the time to clearance in three separate time periods: July 2012-June 2013; July 2013-December 2013; and January 2014-June 2015.
The study showed that approval rates climbed steadily for privately insured patients, from about 85 percent prior to the ACA mandate to approximately 95 percent after the mandate. Also, the privately insured patients experienced fewer delays in being cleared for participation.
Among patients with Medicare or Medicaid coverage, there was no significant association between the referral time period or insurance clearance rate.
Author Comment: Hong explained that timely approvals are crucial for patients who want to participate in clinical trials. He said the fact that the privately insured patients experienced fewer delays indicates that the ACA provision that requires private insurers to cover clinical trial participation had a direct benefit for those patients.
"In a phase I trial, many patients are in a state of advanced disease, so a single day can matter a great deal to them," he said. "We are in a golden era of new drugs, but the only way to get them approved and available to patients is to get more people into clinical trials," Hong said.
The ACA is in a state of flux, as President Donald Trump has vowed to repeal it and a replacement bill crafted by the U.S. Senate has stalled. Hong said that his study's findings indicate that any replacement for the ACA should include provisions to ensure patient access to clinical trials.
"Clinical trials are crucially important in helping get drugs to the patients that need them," Hong said. "This study is one piece of evidence that the ACA is helping more patients get access to these trials."
Limitations: Hong said the study's main limitation is that it was conducted solely at MD Anderson. While he believes that the overall trend of increased coverage would hold true at other institutions, he said further study at other cancer centers with different patient populations could be useful in analyzing the overall impact of the ACA.
Disclosures: Hong and Kehl declare no conflicts of interest. Other authors on the paper have received research funding from Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant or consultant/advisory board fees from Actuate Therapeutics and Xbiotech. One author is an unpaid consultant for Angiochem Inc. and one author has an ownership interest in Novena Inc. and Curematch Inc.
To interview David S. Hong or Kenneth L. Kehl, contact Julia Gunther at firstname.lastname@example.org or 215-446-6896.
Follow us: Cancer Research Catalyst http://blog.aacr.org; Twitter @AACR; and Facebook http://www.facebook.com/aacr.org
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 37,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 108 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 21,900 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.